Chapters

Transcript

Video

In light of the unmet need for improving response rates in relapsed/resistant cases of persons with PTCL-TFH, how did your group identify the dual delta-gamma PI3K inhibitor, duvelisib, for managing R/R cases?


Created by

CMEducation Resources iQ&A PTCL Hematology-Oncology Intelligence Zone

Presenter

Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutchinson Cancer CenterAssistant Professor, Division of Hematology and OncologyUniversity of Washington School of MedicineSeattle, Washington